Association of early kidney allograft failure with preformed IgA antibodies to β2-glycoprotein I

Journal of the American Society of Nephrology

Volumn 26, Issue 3, 2015, Pages 735-745

  Morales, Jose M ^a   Martinez Flores, Jose Angel ^a   Serrano, Manuel ^a   Castro, Maria José ^a   Alfaro, Francisco Javier ^a   García, Florencio ^a   Martínez, Miguel Angel ^a   Andrés, Amado ^a   González, Esther ^a   Praga, Manuel ^a   Paz Artal, Estela ^a,b,c   Serrano, Antonio ^a,b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; BETA2 GLYCOPROTEIN 1 ANTIBODY; CYCLOSPORIN A; IMMUNOGLOBULIN A ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; IMMUNOGLOBULIN A;

ADULT; ARTERY THROMBOSIS; ARTICLE; COHORT ANALYSIS; DELAYED GRAFT FUNCTION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; VEIN THROMBOSIS; BLOOD; IMMUNOLOGY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATION;

AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; DELAYED GRAFT FUNCTION; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN A; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 84924054152     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014030228     Document Type: Article

References (56)

1. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357: 2562-2575, 2007
2. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador GT, Vincenti FG, Cheung M, Earley A, Raman G, Abariga S, Wagner M, Balk EM; Kidney Disease: Improving Global Outcomes: KDIGO clinical practice guideline for the care of kidney transplant recipients: A summary. Kidney Int 77: 299-311, 2010
3. Morales JM, Marcén R, del Castillo D, Andres A, Gonzalez-Molina M, Oppenheimer F, Serón D, Gil-Vernet S, Lampreave I, Gainza FJ, Valdés F, Cabello M, Anaya F, Escuin F, Arias M, Pallardó L, Bustamante J: Risk factors for graft loss and mortality after renal transplantation according to recipient age: A prospective multicentre study. Nephrol Dial Transplant 27[Suppl 4]: iv39-iv46, 2012
4. Ponticelli C, Moia M, Montagnino G: Renal allograft thrombosis. Nephrol Dial Transplant 24: 1388-1393, 2009
5. Morales JM, Marcén R, Andrés A, Molina MG, Castillo DD, Cabello M, Capdevila L, Campistol JM, Oppenheimer F, Serón D, Vernet SG, Lampreave I, Valdés F, Anaya F, Escuín F, Arias M, Pallardó L, Bustamante J: Renal transplantation in themodern immunosuppressive era in Spain: Four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney Int Suppl 11: S94-S99, 2008
6. Terasaki PI, Kreisler M, Mickey RM: Presensitization and kidney transplant failures. Postgrad Med J 47: 89-100, 1971
7. Dragun D, Philippe A, Catar R: Role of non-HLA antibodies in organ transplantation. Curr Opin Organ Transplant 17: 440-445, 2012
8. Wood KJ, Goto R: Mechanisms of rejection: Current perspectives. Transplantation 93: 1-10, 2012
9. Nankivell BJ, Alexander SI: Rejection of the kidney allograft. N Engl J Med 363: 1451-1462, 2010
10. Triplett DA: Antiphospholipid antibodies. Arch Pathol Lab Med 126: 1424-1429, 2002
11. Fischer MJ, Rauch J, Levine JS: The antiphospholipid syndrome. Semin Nephrol 27: 35-46, 2007
12. de Groot PG, Urbanus RT: The significance of autoantibodies against β2-glycoprotein I. Blood 120: 266-274, 2012
13. Ragusa MA, Costa S, Cefalú AB, Noto D, Fayer F, Travali S, Averna MR, Gianguzza F: RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues. Int J Mol Med 18: 449-455, 2006
14. Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, Palomo I, Harris EN, Meroni PL: Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenic mechanisms. Semin Thromb Hemost 34: 236-250, 2008
15. Moestrup SK, Schousboe I, Jacobsen C, Leheste JR, Christensen EI, Willnow TE: Beta2-glycoprotein-I (apolipoprotein H) and beta2-glycoprotein-I-phospholipid complex harbor a recognition site for the endocytic receptor megalin. J Clin Invest 102: 902-909, 1998
16. Klaerke DA, Røjkjaer R, Christensen L, Schousboe I: Identification of beta2-glycoprotein I as a membrane-associated protein in kidney: Purification by calmodulin affinity chromatography. Biochim Biophys Acta 1339: 203-216, 1997
17. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295-306, 2006
18. Murthy V, Willis R, Romay-Penabad Z, Ruiz-Limon P, Martinez-Martinez LA, Jatwani S, Jajoria P, Seif A, Alarcon GS, Papalardo E, Liu J, Vila LM, McGwin G Jr., McNearney TA, Maganti R, Sunkureddi P, Parekh T, Tarantino M, Akhter E, Fang H, Gonzalez EB, Binder W, Norman G, Teodorescu M, Reveille JD, Petri M, Pierangeli SS: Value of isolated IgA anti-β-glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 65: 3186-3193, 2013
19. Ruiz-García R, Serrano M, Martínez-Flores JÁ, Mora S, Morillas L, Martín-Mola MA, Morales JM, Paz-Artal E, Serrano A: Isolated IgA anti-β2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome. J Immunol Res 2014: 704395, 2014
20. Martinez-Flores JA, Serrano M, Alfaro J, Mora S, Paz-Artal E, Morales JM, Serrano A: Heterogeneity between diagnostic tests for IgA anti-beta2 glycoprotein I: Explaining the controversy in studies of association with vascular pathology. Anal Chem 85: 12093-12098, 2013
21. Uthman I, Khamashta M: Antiphospholipid syndrome and the kidneys. Semin Arthritis Rheum 35: 360-367, 2006
22. Grönhagen-Riska C, Teppo AM, Helanterä A, Honkanen E, Julkunen H: Raised concentrations of antibodies to cardiolipin in patients receiving dialysis. BMJ 300: 1696-1697, 1990
23. Brunet P, Aillaud MF, San Marco M, Philip-Joet C, Dussol B, Bernard D, Juhan-Vague I, Berland Y: Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int 48: 794-800, 1995
24. Serrano A, García F, Serrano M, Ramírez E, Alfaro FJ, Lora D, de la Cámara AG, Paz-Artal E, Praga M, Morales JM: IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney Int 81: 1239-1244, 2012
25. Hadhri S, Rejeb MB, Belarbia A, Achour A, Skouri H: Hemodialysis duration, human platelet antigen HPA-3 and IgA isotype of anti-β2glycoprotein I antibodies are associated with native arteriovenous fistula failure in Tunisian hemodialysis patients. Thromb Res 131: e202-e209, 2013
26. Perico N, Cattaneo D, Sayegh MH, Remuzzi G: Delayed graft function in kidney transplantation. Lancet 364: 1814-1827, 2004
27. Phelan PJ, O'Kelly P, Tarazi M, Tarazi N, Salehmohamed MR, Little DM, Magee C, Conlon PJ: Renal allograft loss in the first post-operative month: Causes and consequences. Clin Transplant 26: 544-549, 2012
28. Cole EH, Johnston O, Rose CL, Gill JS: Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 3: 814-821, 2008
29. El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, Cosio FG: Identifying specific causes of kidney allograft loss. Am J Transplant 9: 527-535, 2009
30. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD: A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 41: 924-929, 2002
31. Giessing M, Budde K, Fritsche L, Slowinski T, Tuerk I, Schoenberger B, Neumayer HH, Loening SA: "Old-for-old" cadaveric renal transplantation: Surgical findings, perioperative complications and outcome. Eur Urol 44: 701-708, 2003
32. Andrés A, Morales JM, Herrero JC, Praga M, Morales E, Hernández E, Ortuño T, Rodício JL, Martínez MA, Usera G, Díaz R, Polo G, Aguirre F, Leiva O: Double versus single renal allografts from aged donors. Transplantation 69: 2060-2066, 2000
33. Dinavahi R, George A, Tretin A, Akalin E, Ames S, Bromberg JS, Deboccardo G, Dipaola N, Lerner SM, Mehrotra A, Murphy BT, Nadasdy T, Paz-Artal E, Salomon DR, Schröppel B, Sehgal V, Sachidanandam R, Heeger PS: Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol 22: 1168-1178, 2011
34. Mahdi BM: A glow of HLA typing in organ transplantation. Clin Transl Med 2: 6, 2013
35. Tinckam KJ, Chandraker A: Mechanisms and role of HLA and non-HLA alloantibodies. Clin J Am Soc Nephrol 1: 404-414, 2006
36. Win TS, Pettigrew GJ: Humoral autoimmunity and transplant vasculopathy: When allo is not enough. Transplantation 90: 113-120, 2010
37. Nakagawa Y, Saito K, Morioka T, Tomita Y, Takahashi K, Oite T: The clinical significance of antibody to vascular endothelial cells after renal transplantation. Clin Transplant 16[Suppl 8]: 51-57, 2002
38. Pober JS, Orosz CG, Rose ML, Savage CO: Can graft endothelial cells initiate a host anti-graft immune response? Transplantation 61: 343-349, 1996
39. Sumitran-Karuppan S, Tyden G, Reinholt F, Berg U, Moller E: Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 5: 321-327, 1997
40. Sun Q, Liu Z, Chen J, Chen H, Wen J, Cheng D, Li L: Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection. Clin J Am Soc Nephrol 3: 1479-1486, 2008
41. Dunoyer-Geindre S, Kruithof EK, Galve-de Rochemonteix B, Rosnoblet C, Gruenberg J, Reber G, de Moerloose P: Localization of beta2-glycoprotein 1 in late endosomes of human endothelial cells. Thromb Haemost 85: 903-907, 2001
42. Kornberg A, Renaudineau Y, Blank M, Youinou P, Shoenfeld Y: Anti-beta 2-glycoprotein I antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells. Isr Med Assoc J 2[Suppl]: 27-31, 2000
43. Pierangeli SS, Harris EN: Probing antiphospholipid-mediated thrombosis: The interplay between anticardiolipin antibodies and endothelial cells. Lupus 12: 539-545, 2003
44. Brandt KJ, Kruithof EK, de Moerloose P: Receptors involved in cell activation by antiphospholipid antibodies. Thromb Res 132: 408-413, 2013
45. Meroni PL, Borghi MO, Raschi E, Tedesco F: Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat Rev Rheumatol 7: 330-339, 2011
46. Shoenfeld Y, BlankM, Cervera R, Font J, Raschi E, Meroni PL: Infectious origin of the antiphospholipid syndrome. Ann RheumDis 65: 2-6, 2006
47. George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, Barshack I, Kopolovic J, Shoenfeld Y: Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: Potential implications for lesion progression. Circulation 99: 2227-2230, 1999
48. Willis R, Harris EN, Pierangeli SS: Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost 38: 305-321, 2012
49. Cruz-Tapias P, Blank M, Anaya JM, Shoenfeld Y: Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol 24: 389-393, 2012
50. Serrano M, Martínez-Flores JA, Castro MJ, García F, Lora D, Perez D, Gonzalez E, Paz-Artal E, Morales JM, Serrano A: Renal transplantation dramatically reduces IgA anti-beta-2-glycoprotein I antibodies in patients with endstage renal disease. J Immunol Res 2014: 641962, 2014
51. Wagenknecht DR, Becker DG, LeFor WM, McIntyre JA: Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation 68: 241-246, 1999
52. Forman JP, Lin J, Pascual M, Denton MD, Tolkoff-Rubin N: Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation. Am J Transplant 4: 1786-1791, 2004
53. Fernández-Fresnedo G, López-Hoyos M, Segundo DS, Crespo J, Ruiz JC, De Francisco AL, Arias M: Clinical significance of antiphospholipid antibodies on allograft and patient outcome after kidney transplantation. Transplant Proc 37: 3710-3711, 2005
54. De Serres SA, Isenring P: Renal thrombotic microangiopathy revisited: When a lesion is not a clinical finding. Saudi J Kidney Dis Transpl 21: 411-416, 2010
55. Keller AK, Jorgensen TM, Jespersen B: Identification of risk factors for vascular thrombosis may reduce early renal graft loss: A review of recent literature. J Transplant 2012: 793461, 2012
56. Patel R, Terasaki PI: Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280: 735-739, 1969